# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...
Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...
Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.
The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act (PDUFA) action goal date...
Wells Fargo analyst Cerena Chen initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Overweight rating and announc...